Immunogenicity of COVID-19 vaccines in lung cancer patients
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
OBJECTIVE: Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy of anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed at evaluating the safety and immunogenicity of COVID-19 vaccines in this population.
PATIENTS AND METHODS: The prospective, nationwide SOLID substudy, enrolled adults with lung cancer who were fully vaccinated against COVID-19. Serum anti-SARS-CoV-2 IgG antibody levels were quantitatively assessed two weeks and six months after receipt of the last dose using a chemiluminescent microparticle immunoassay. Multivariate odds ratios for the association between demographic and clinical factors and seronegativity after vaccination were estimated.
RESULTS: 1973 lung cancer patients were enrolled. Most patients had stage IV disease (66%) and were receiving active cancer treatment (82.7%). No significant differences were found in the probability of being seronegative for anti-SARS-CoV-2 IgG antibodies after full vaccination between patients who were receiving active cancer treatment and those who were not (p = 0.396). The administration of immunotherapy or oral targeted therapy and immunization with mRNA-1273 COVID-19 vaccine were factors independently associated with increased odds of being seropositive after vaccination. From all patients, 1405 received the second dose of vaccine and high levels of antibody titers were observed in 93.6% of patients two weeks after second dose. At six months, multivariate logistic regression analysis showed that performance status ≥ 2 was independently associated with a higher probability of being seronegative after full vaccination with an OR 4.15. On the other hand, received chemotherapy or oral target therapy and vaccination with mRNA-1273 were a factor independently associated with lower odds of being seronegative after full vaccination with an OR 0.52, 0.37 and 0.34, respectively.
CONCLUSIONS: Lung cancer patients can safely achieve a strong immune response against SARS-CoV-2 after full vaccination, regardless of the cancer treatment received.
TRIAL REGISTRATION: NCT04407143.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:184 |
|---|---|
| Enthalten in: |
Lung cancer (Amsterdam, Netherlands) - 184(2023) vom: 05. Okt., Seite 107323 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 19.09.2023 Date Revised 26.09.2023 published: Print-Electronic ClinicalTrials.gov: NCT04407143 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lungcan.2023.107323 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361379188 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361379188 | ||
| 003 | DE-627 | ||
| 005 | 20231226085019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2023.107323 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361379188 | ||
| 035 | |a (NLM)37639820 | ||
| 035 | |a (PII)S0169-5002(23)00861-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Provencio, Mariano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity of COVID-19 vaccines in lung cancer patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.09.2023 | ||
| 500 | |a Date Revised 26.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04407143 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVE: Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy of anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed at evaluating the safety and immunogenicity of COVID-19 vaccines in this population | ||
| 520 | |a PATIENTS AND METHODS: The prospective, nationwide SOLID substudy, enrolled adults with lung cancer who were fully vaccinated against COVID-19. Serum anti-SARS-CoV-2 IgG antibody levels were quantitatively assessed two weeks and six months after receipt of the last dose using a chemiluminescent microparticle immunoassay. Multivariate odds ratios for the association between demographic and clinical factors and seronegativity after vaccination were estimated | ||
| 520 | |a RESULTS: 1973 lung cancer patients were enrolled. Most patients had stage IV disease (66%) and were receiving active cancer treatment (82.7%). No significant differences were found in the probability of being seronegative for anti-SARS-CoV-2 IgG antibodies after full vaccination between patients who were receiving active cancer treatment and those who were not (p = 0.396). The administration of immunotherapy or oral targeted therapy and immunization with mRNA-1273 COVID-19 vaccine were factors independently associated with increased odds of being seropositive after vaccination. From all patients, 1405 received the second dose of vaccine and high levels of antibody titers were observed in 93.6% of patients two weeks after second dose. At six months, multivariate logistic regression analysis showed that performance status ≥ 2 was independently associated with a higher probability of being seronegative after full vaccination with an OR 4.15. On the other hand, received chemotherapy or oral target therapy and vaccination with mRNA-1273 were a factor independently associated with lower odds of being seronegative after full vaccination with an OR 0.52, 0.37 and 0.34, respectively | ||
| 520 | |a CONCLUSIONS: Lung cancer patients can safely achieve a strong immune response against SARS-CoV-2 after full vaccination, regardless of the cancer treatment received | ||
| 520 | |a TRIAL REGISTRATION: NCT04407143 | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a Neutralizing antibodies | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Estival, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a López-Vivanco, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Saigí, María |e verfasserin |4 aut | |
| 700 | 1 | |a Arasanz, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Diz, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Carcereny, Enric |e verfasserin |4 aut | |
| 700 | 1 | |a García, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Mosquera, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Iruarrizaga, Eluska |e verfasserin |4 aut | |
| 700 | 1 | |a Majem, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch-Barrera, Joaquim |e verfasserin |4 aut | |
| 700 | 1 | |a Mielgo-Rubio, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Guirado, María |e verfasserin |4 aut | |
| 700 | 1 | |a Juan-Vidal, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Blasco, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Lucía Gozálvez, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Del Barrio, Anabel |e verfasserin |4 aut | |
| 700 | 1 | |a De Portugal, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a López-Martín, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Begoña |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Catot, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Martí-Ciriquian, Juan Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Del Barco, Edel |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo, Virginia |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish Lung Cancer Group (SLGC/GECP) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer (Amsterdam, Netherlands) |d 1994 |g 184(2023) vom: 05. Okt., Seite 107323 |w (DE-627)NLM074973657 |x 1872-8332 |7 nnns |
| 773 | 1 | 8 | |g volume:184 |g year:2023 |g day:05 |g month:10 |g pages:107323 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lungcan.2023.107323 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 184 |j 2023 |b 05 |c 10 |h 107323 | ||